Peer-influenced content. Sources you trust. No registration required. This is HCN.
Blood
Major advances in the understanding of acute myeloid leukemia (AML) has prompted the need for this update, which includes a revised European LeukemiaNet (ELN) genetic risk classification, revised response criteria, and treatment recommendations from the 2010 and 2017 editions.
Hematology/Oncology July 18th 2022
ReachMD
Offering 0.25 credits, this 30-minute CME program discusses the new cervical cancer screening guidelines recently published by both the American Society for Colonoscopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS).
Obstetrics & Gynecology July 13th 2022
MDLinx
In a look “Beyond the Guidelines,” a preventive cardiologist and a general internist discuss their approach in the case of a 57-year-old woman with high cholesterol and a family history of heart disease.
Cardiology June 23rd 2022
Harvard assistant professor of psychiatry comments on a new trend to treat BPD by generalists using brief steps of care. This approach enables clinicians who are not specialists to diagnose the disorder and guide the patient in navigating care one step at a time — in any clinical setting.
Psychiatry June 7th 2022
Cancer Therapy Advisor
Per guidelines, cancers with HER2 expression with a score of 3+ was considered HER2-positive. Cancers with scores of 0 and 1+, or those with an IHC score of 2+ and a negative ISH result, have been characterized as HER2-negative. These guideline-directed binary distinctions — HER2-positive vs HER2-negative — have until now guided physicians’ treatment decisions. New research suggests that patients with HER2-2+, ISH-negative breast cancer present a clinical picture closer to that of patients with HER2-positive breast cancer.
Oncology, Medical June 6th 2022
Medical Professionals Reference (MPR)
The CDC continue to recommend Paxlovid for early-stage treatment of mild-to-moderate COVID-19 among individuals at high risk of progression to severe disease. Recent case reports suggest that some patients treated with Paxlovid may have a recurrence of COVID-19 symptoms two to eight days after completing the five-day course of treatment. Both the illness and the positive test results resolved, on average, three days later without the need for additional treatment.
All Specialties May 31st 2022